UAB Digital Repository of Documents 12 records found  1 - 10next  jump to record: Search took 0.01 seconds. 
1.
14 p, 2.2 MB Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer / Aguado, Cristina (Quirón Dexeus University Hospital) ; Teixido, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Román, Ruth (Quirón Dexeus University Hospital) ; Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ; Giménez-Capitán, Ana (Quirón Dexeus University Hospital) ; Marin, Elba (Hospital Clínic i Provincial de Barcelona) ; Cabrera, Carlos (Grup Quirónsalud (Barcelona, Catalunya)) ; Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ; Castillo, Sergi (Hospital General de Granollers) ; Muñoz, Silvia (Hospital General de Granollers) ; Arcocha, Ainara (Hospital Clínic i Provincial de Barcelona) ; López-Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ; Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ; Aldeguer, Erika (Quirón Dexeus University Hospital) ; Rodríguez, Sonia (Quirón Dexeus University Hospital) ; Moya, Irene (Grup Quirónsalud (Barcelona, Catalunya)) ; Viteri, Santiago (Quiron Salud Group) ; Cardona, Andrés Felipe (Clínica del Country) ; Palmero, Ramon (L'Hospitalet) ; Sainz, Cristina (Centro de Investigación Biomédica en Red de Cáncer) ; Mesa-Guzmán, Miguel (Universidad Pública de Navarra) ; Lozano, Maria D. (Universidad Pública de Navarra) ; Aguilar-Hernández, Andrés (Grup Quirónsalud (Barcelona, Catalunya)) ; Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ; González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ; Gonzalvo, Elena (Hospital Clínic i Provincial de Barcelona) ; Leenders, William P. J. (Radboud Institute for Molecular Life Sciences) ; Rosell, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina) ; Montuenga, Luis M. (Universidad Pública de Navarra) ; Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ; Molina-Vila, Miguel Angel (Quirón Dexeus University Hospital) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona)
We studied MET alterations in 474 advanced non-small-cell lung cancer (NSCLC) patients by nCounter, an RNA-based technique. We identified 3% with MET Δex14 mRNA and 3. 5% with very-high MET mRNA expression, a surrogate of MET amplification. [...]
2020 - 10.1002/1878-0261.12861
Molecular Oncology, Vol. 15 (december 2020) , p. 350-363  
2.
14 p, 572.1 KB Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer / Frigola Rissech, Joan (Vall d'Hebron Institut d'Oncologia) ; Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ; Carbonell, Caterina (Vall d'Hebron Institut d'Oncologia) ; Callejo, Anna (Vall d'Hebron Institut d'Oncologia) ; Iranzo, Patricia (Vall d'Hebron Institut d'Oncologia) ; Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ; Martinez-Martí, Alex (Vall d'Hebron Institut d'Oncologia) ; Pardo, Nuria (Vall d'Hebron Institut d'Oncologia) ; Saoudi-Gonzalez, Nadia (Vall d'Hebron Institut d'Oncologia) ; Martinez, D. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Jiménez, José (Vall d'Hebron Institut d'Oncologia) ; Sansano, Irene (Hospital Universitari Vall d'Hebron) ; Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Montuenga, L.M. (Navarra Health Research Institute (IDISNA)) ; Sánchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Prat, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ; Amat, Ramón (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Immunotherapy has transformed advanced non-small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long-lasting responses in some patients. However, the molecular determinants driving these long-term responses remain elusive. [...]
2020 - 10.1002/1878-0261.12891
Molecular Oncology, 2020  
3.
24 p, 1.6 MB The DNA methylation landscape of hematological malignancies : an update / Blecua, Pedro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martínez-Verbo, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Esteller, M. (Universitat de Barcelona. Facultat de Medicina) ; Universitat Autònoma de Barcelona
The rapid advances in high-throughput sequencing technologies have made it more evident that epigenetic modifications orchestrate a plethora of complex biological processes. During the last decade, we have gained significant knowledge about a wide range of epigenetic changes that crucially contribute to some of the most aggressive forms of leukemia, lymphoma, and myelodysplastic syndromes. [...]
2020 - 10.1002/1878-0261.12744
Molecular Oncology, Vol. 14 Núm. 8 (january 2020) , p. 1616-1639  
4.
14 p, 892.1 KB Discovery of novel DNA methylation biomarkers for non-invasive sporadic breast cancer detection in the Latino population / Cappetta, M. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ; Fernandez, L. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ; Brignoni, L. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ; Artagaveytia, N. (Departamento Básico de Medicina. Facultad de Medicina. Universidad de la República) ; Bonilla, C. (Population Health Sciences. Bristol Medical School. University of Bristol) ; López, Miguel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bertoni, B. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ; Berdasco, Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Human diversity is one of the main pitfalls in the development of robust worldwide biomarkers in oncology. Epigenetic variability across human populations is associated with different genetic backgrounds, as well as variable lifestyles and environmental exposures, each of which should be investigated. [...]
2021 - 10.1002/1878-0261.12842
Molecular Oncology, Vol. 15 Núm. 2 (february 2021) , p. 473-486  
5.
16 p, 1.9 MB Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients / Ji, X. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ; Lin, L. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ; Shen, S. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ; Dong, X. (Department of Epidemiology and Biostatistics. School of Public Health. Southeast University) ; Chen, C. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ; Li, Y. (Department of Biostatistics. University of Michigan) ; Zhu, Y. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ; Huang, H. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ; Chen, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ; Chen, X. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ; Wei, Liangmin (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ; He, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ; Duan, W. (Department of Bioinformatics. School of Biomedical Engineering and Informatics. Nanjing Medical University) ; Su, L. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ; Jiang, Y. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ; Fan, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ; Guan, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ; You, D. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ; Shafer, A. (Harvard Medical School) ; Bjaanæs, M.M. (Department of Cancer Genetics. Institute for Cancer Research. Oslo University Hospital) ; Karlsson, A. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ; Planck, M. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ; Staaf, J. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ; Helland, Å. (Institute of Clinical Medicine. University of Oslo) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Wei, Y. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ; Zhang, R. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ; Chen, F. (Jiangsu Key Lab of Cancer Biomarkers. Prevention and Treatment. Cancer Center. Collaborative Innovation Center for Cancer Personalized Medicine. Nanjing Medical University) ; Christiani, D.C. (Harvard Medical School) ; Universitat Autònoma de Barcelona
Tripartite motif containing 27 (TRIM27) is highly expressed in lung cancer, including non-small-cell lung cancer (NSCLC). Here, we profiled DNA methylation of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tumours from 613 early-stage NSCLC patients and evaluated associations between CpG methylation of TRIM27 and overall survival. [...]
2020 - 10.1002/1878-0261.12785
Molecular Oncology, Vol. 14 Núm. 11 (january 2020) , p. 2759-2774  
6.
15 p, 1.9 MB Silencing of adaptor protein 32 reduces / receptors expression and impairs gastrointestinal stromal tumors growth / Serrano-Candelas, Eva (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Ainsua Enrich, Erola (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Navinés-Ferrer, Arnau (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Rodrigues, Paulo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ; Bazzocco, Sarah (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ; Macaya, Irati (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín (Universitat Autònoma de Barcelona) ; Serrano, César (Hospital Universitari Vall d'Hebron) ; Sayós, Joan (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Martin, Margarita (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Gastrointestinal stromal tumors (s) represent about 80% of the mesenchymal neoplasms of the gastrointestinal tract. Most s contain oncogenic (85%) or (5%) receptors. The kinase inhibitor imatinib mesylate is the preferential treatment for these tumors; however, the development of drug resistance has highlighted the need for novel therapeutic strategies. [...]
2018 - 10.1002/1878-0261.12332
Molecular Oncology, Vol. 12 (june 2018) , p. 1383-1397  
7.
4 p, 147.6 KB Towards a Cancer Mission in Horizon Europe / Berns, Anton (European Academy of Cancer Sciences) ; Ringborg, Ulrik (Karolinska University Hospital) ; Eggermont, Alexander (Gustave Roussy Cancer Campus Grand Paris) ; Baumann, Michael (German Cancer Consortium) ; Calvo, Fabien (Gustave Roussy Cancer Campus Grand Paris) ; Eggert, Angelika (Charite-Universitatsmedizin) ; Espina, Carolina (International Agency for Research on Cancer) ; Hanahan, Douglas (Federal Institute of Technology in Lausanne) ; Lacombe, Denis (EORTC Headquarters) ; de Lorenzo, Francesco (European Cancer Patient Coalition) ; Oberst, Simon (Organisation of European Cancer Institutes) ; Philip, Thierry (Institut Curie) ; Schüz, Joachim (International Agency for Research on Cancer) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Celis, Julio E. (Danish Cancer Society Research Centre) ; Universitat Autònoma de Barcelona
2019 - 10.1002/1878-0261.12585
Molecular Oncology, Vol. 13 (october 2019) , p. 2301-2304  
8.
986.5 KB Finding MYCure / Beaulieu, Marie-Eve (Peptomyc S.L.) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. [...]
2019 - 10.1080/23723556.2019.1618178
Molecular & cellular oncology, Vol. 6, Num. 5 (June 2019) , art. e1618178  
9.
9 p, 297.7 KB New clinical trial designs in the era of precision medicine / Garralda, Elena (Universitat Autònoma de Barcelona) ; Dienstmann, Rodrigo (Universitat Autònoma de Barcelona) ; Piris-Giménez, Alejandro (Universitat Autònoma de Barcelona) ; Braña, Irene (Universitat Autònoma de Barcelona) ; Rodon Ahnert, Jordi (Universitat Autònoma de Barcelona) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Universitat Autònoma de Barcelona ; VHIO Vall d'Hebron Institut d'Oncologia
Cancer treatment has made significant strides towards the promise of personalized medicine. Recent scientific advances have shown that there are numerous genetic deregulations that are common in multiple cancer types, raising the possibility of developing drugs targeting those deregulations irrespective of the tumour type. [...]
2019 - 10.1002/1878-0261.12465
Molecular Oncology, Vol. 13 (february 2019) , p. 549-557  
10.
19 p, 2.2 MB 1ε and p120-catenin control Ror2 function in noncanonical Wnt signaling / Curto Navarro, Josué (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; del Valle Pérez, Beatriz (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Villarroel, Aida (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Fuertes, Guillem (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Vinyoles, Meritxell (Institut Hospital del Mar d'Investigacions Mèdiques) ; Peña, Raúl (Institut Hospital del Mar d'Investigacions Mèdiques) ; García de Herreros, Antonio (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut) ; Dunach, Mireia (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Canonical and noncanonical Wnt pathways share some common elements but differ in the responses they evoke. Similar to Wnt ligands acting through the canonical pathway, Wnts that activate the noncanonical signaling, such as Wnt5a, promote Disheveled (Dvl) phosphorylation and its binding to the Frizzled (Fz) Wnt receptor complex. [...]
2018 - 10.1002/1878-0261.12184
Molecular Oncology, Vol. 12, issue 5 (May 2018) , p. 611-629  

UAB Digital Repository of Documents : 12 records found   1 - 10next  jump to record:
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.